|
1
|
Di Marco M, Di Cicilia R, Macchini M,
Nobili E, Vecchiarelli S, Brandi G and Biasco G: Metastatic
pancreatic cancer: Is gemcitabine still the best standard
treatment? (Review). Oncol Rep. 23:1183–1192. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sen N, Falk S and Abrams R: Role of
chemoradiotherapy in the adjuvant and neoadjuvant settings for
resectable pancreatic cancer. Clin Oncol (R Coll Radiol).
26:551–559. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Seufferlein T, Bachet JB, Van Cutsem E and
P; ESMO Guidelines Working Group Rougier: Pancreatic
adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 23 Suppl
7:vii33–vii40. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Preis M and Korc M: Kinase signaling
pathways as targets for intervention in pancreatic cancer. Cancer
Biol Ther. 9:754–763. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kleger A, Perhofer L and Seufferlein T:
Smarter drugs emerging in pancreatic cancer therapy. Ann Oncol.
25:1260–1270. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vaccaro V, Sperduti I and Milella M:
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N
Engl J Med. 365:768–769. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gourgou-Bourgade S, Bascoul-Mollevi C,
Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A,
Raoul JL, Boige V, et al: Impact of FOLFIRINOX compared with
gemcitabine on quality of life in patients with metastatic
pancreatic cancer: Results from the PRODIGE 4/ACCORD 11 randomized
trial. J Clin Oncol. 31:23–29. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tabernero J, Chiorean EG, Infante JR,
Hingorani SR, Ganju V, Weekes C, Scheithauer W, Ramanathan RK,
Goldstein D, Penenberg DN, et al: Prognostic factors of survival in
a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus
gemcitabine versus gemcitabine alone in patients with metastatic
pancreatic cancer. Oncologist. 20:143–150. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Neoptolemos JP, Stocken DD, Friess H,
Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C,
Lacaine F, et al: A randomized trial of chemoradiotherapy and
chemotherapy after resection of pancreatic cancer. N Engl J Med.
350:1200–1210. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Neoptolemos JP, Stocken DD, Bassi C,
Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger
S, Mariette C, et al: Adjuvant chemotherapy with fluorouracil plus
folinic acid vs gemcitabine following pancreatic cancer resection:
A randomized controlled trial. JAMA. 304:1073–1081. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miller RC, Iott MJ and Corsini MM: Review
of adjuvant radiochemotherapy for resected pancreatic cancer and
results from Mayo Clinic for the 5th JUCTS symposium. Int J Radiat
Oncol Biol Phys. 75:364–368. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chuong MD, Boggs DH, Patel KN and Regine
WF: Adjuvant chemoradiation for pancreatic cancer: What does the
evidence tell us? J Gastrointest Oncol. 5:166–177. 2014.PubMed/NCBI
|
|
14
|
Ouettle H, Neuhaus P, Hochhaus A, Hartmann
JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J,
Arning MB, et al: Adjuvant chemotherapy with gemcitabine and
long-term outcomes among patients with resected pancreatic cancer:
The CONKO-001 randomized trial. JAMA. 310:1473–1481. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Regine WF, Winter KA, Abrams R, Safran H,
Hoffman JP, Konski A, Benson AB, Macdonald JS, Rich TA and Willett
CG: Fluorouracil-based chemoradiation with either gemcitabine or
fluorouracil chemotherapy after resection of pancreatic
adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704
phase III trial. Ann Surg Oncol. 18:1319–1326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Moghanaki D, Mick R, Furth EE, Sohal D,
Salmon PM, Behbahani A, Morgans AK, Miller SM, Giantonio BJ,
Whittington RW, et al: Resection status, age and nodal involvement
determine survival among patients receiving adjuvant
chemoradiotherapy in pancreatic adenocarcinoma. JOP. 12:438–444.
2011.PubMed/NCBI
|
|
17
|
Herman JM, Swartz MJ, Hsu CC, Winter J,
Pawlik TM, Sugar E, Robinson R, Laheru DA, Jaffee E, Hruban RH, et
al: Analysis of fluorouracil-based adjuvant chemotherapy and
radiation after pancreaticoduodenectomy for ductal adenocarcinoma
of the pancreas: Results of a large, prospectively collected
database at the Johns Hopkins Hospital. J Clin Oncol. 26:3503–3510.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: A phase III trial of the
National Cancer Institute of Canada Clinical Trials group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
|
